

Supporting Information

AIE active luminogen derived using 2-hydroxy-1-naphthaldehyde and 3- hydroxy-2-naphthohydrazide for the detection of sparfloxacin and azithromycin

Dhvani A. Patel^a, Bigyan R. Jali^b and Suban K. Sahoo^{a*}

^a Department of Chemistry, Sardar Vallabhbhai National Institute of Technology, Surat-395007, Gujarat, India.

^b Department of Chemistry, Veer Surendra Sai University of Technology, Burla, Sambalpur-768018, Odisha, India.

*Corresponding author (Dr. Sahoo): sks@chem.svnit.ac.in.

Dept. of Chemistry, IIT Roorkee




Sample Information

Name	AS_Barkha_310724_HN	Data File Path	D:\Projects\SEP_2023\Data\Jul_2024\AS_Barkha_310724_HN.d
Sample ID		Acq. Time (Local)	31-07-2024 12:58:48 (UTC+05:30)
Instrument	LCQTOF	Method Path (Acq)	D:\Projects\SEP_2023\METHODS\POSITIVE.m
MS Type	QTOF	Version (Acq SW)	6200 series TOF/6500 series Q-TOF (11.0.203.0)
Inj. Vol. (μl)	2	IRM Status	Success
Position	P1-A2	Method Path (DA)	D:\Projects\INSTALLATION\METHODS\IIT Roorkee.m
Plate Pos.		Target Source Path	
Operator	SYSTEM (SYSTEM)	Result Summary	1 qualified (1 targets)

Sample Spectra

+ Scan (rt: 0.146 min)




Compound Details

Cpd. 1: C22 H16 N2 O3

Formula	Mass	Score	Algorithm	Diff (Tgt, ppm)	Polarity
C22 H16 N2 O3	356.1161	99.66	FBF	0.0350825925363825	Positive

Compound Spectra (overlaid)



MassHunter Qual 10.0
(End of Report)

Fig. S1. Mass spectrum of NANH.




Fig. S2. FTIR spectrum of NANH.




Fig. S3. (a) The detectable color changes under UV light (365 nm) and (b) fluorescence spectral changes of NANH (50 μ M, f_{HEPES} 95%, pH 7.4) in the absence and presence of various analytes (50 μ M).




Fig. S4. The BH plot of AIEgen NANH with detected analytes (a) sparfloxacin and (c) azithromycin. The Stern Volmer plot of AIEgen NANH with detected analytes (b) sparfloxacin and (d) azithromycin.




Fig. S5. The UV-Vis absorption spectral changes of NANH ($50 \mu\text{M}$, $f_{\text{HEPES}} 95\%$) upon gradual incremental addition of (a) sparfloxacin and (b) azithromycin.




Fig. S6. DLS profile of AIEgen NANH ($50 \mu\text{M}$, $f_{\text{HEPES}} 95\%$) after adding sparfloxacin and azithromycin ($50 \mu\text{M}$).




Fig. S7. Zeta potential values of AlEgen NANH in the absence and presence of azithromycin and sparfloxacin.

Table S1. Real sample analysis of sparfloxacin in blood serum.

Sparfloxacin			
Added, M	Found, M	Recovery %	± RSD
1.96×10^{-5}	1.88×10^{-5}	95.91 %	0.68
2.20×10^{-5}	2.12×10^{-5}	96.36 %	1.06
2.43×10^{-5}	2.40×10^{-5}	98.76 %	0.96

Table S2. Real sample analysis of azithromycin in blood serum.

Azithromycin			
Added, M	Found, M	Recovery %	± RSD
1.23×10^{-5}	1.18×10^{-5}	95.93 %	1.35
1.47×10^{-5}	1.45×10^{-5}	98.63 %	2.04
1.71×10^{-5}	1.70×10^{-5}	99.41 %	0.77
